New Antiglaucoma Nano-Based Drug Carrier Proposed

A new publication in the journal Carbohydrate Polymers focuses on the creation of a novel chitosan -graphene quantum dots (CS-GQDs) nanocomposite for the administration of latanoprost (LP), an antiglaucoma medication.

New Antigalucoma Nano-Based Drug Carrier Proposed

Study: Novel chitosan - graphene quantum dots composite for therapeutic delivery and tracking through enzymatic stimuli response. Image Credit: sebra/

The development of high-performance and biodegradable nanocomposites with versatile administration and monitoring properties is desirable for future medical applications.

Significance of Graphene Quantum Dots (GQDs)

Graphene quantum dots (GQDs) are generated by exfoliating graphene oxide and possess unique physical and chemical properties.

The size-dependent photoluminescence (PL) property of GQDs greatly increases their usage in bio-imaging and drug delivery applications. GQD photoluminescence is believed to be caused by band-gap creation, heteroatom absorption, enhanced surface oxygen functionality, extremely active borders, and cringle-crangle topologies of GQD nanostructures.

Previously, luminous substances such as semiconductor inorganic compounds and pigments were used to monitor drug administration. Although semiconductor materials have the same fluorescent sensing capabilities as GQDs, they are often considered to be hazardous to live organisms. Furthermore, during stimulation, semiconductor materials tend to create oxidants, which contributes to the list of problems.

Given the constraints of semiconductor materials, GQDs have shown tremendous promise for drug delivery systems because of their diverse qualities such as non-toxicity, controllable stimulation, in vivo, and in vitro detection.

Synthesis of Novel CS-GQDs Nanocomposite for Drug Delivery Applications

In this study, the researchers investigated the possibility of using novel chitosan (CS)- graphene quantum dots (GQDs) nanocomposite for combined drug administration and bioimaging in response to enzymatic stimulation.

Chitosan was employed because of its increased bioactivity, excellent biocompatibility, cationic characteristics, and stimuli-responsive disintegration behavior, which makes it useful in a variety of biomedical applications. The researchers tested the effectiveness of manufactured CS-GQDs nanocomposite in drug delivery applications using latanoprost (LP), an anti-glaucoma medicine.

The GQDs were prepared using previously established procedures that were slightly modified. 2 ml of graphene oxide was put in a round bottom (RB) jar, and to oxidize it, a 3:1 mixture of sulphuric and nitric acid was added.

The RB flask was ultrasonically mixed for approximately two hours to achieve homogenous reagent dispersion. The reaction was performed at 120°C for about 24 hours, with frequent mixing, until the blackish liquid became yellow. GQD formation could be seen as a yellow fluid. The resultant fluid was centrifuged at 1000 rpm for 10 minutes, followed by hemodialysis for 24 hours, to recover pure GQDs. The GQDs that emerged were freeze-dried and kept in the refrigerator for further testing.

Characterization and Analysis of the CS-GQD Nanocomposite

The produced nanocomposite was optically characterized utilizing techniques such as UV-Visible spectroscopy, Emission spectrometry, and Fourier Transform-Infrared spectroscopic analysis using the attenuated total reflectance phase.

High Fidelity electron microscopy and Field Emission imaging were used to study the surface morphology of the graphene quantum dots. The chemical concentrations were examined using X-ray photoelectron spectroscopy (XPS). Moreover, the drug was analyzed using the high-performance liquid chromatography (HPLC) technique. Encapsulation efficiency and band-gap were also calculated using analytical formulas to estimate the drug delivery effectiveness of CS-GQDs nanocomposite.

Key Findings of the Research

In this work, a novel chitosan (CS)-graphene quantum dots (GQD) nanocomposite was effectively created for the administration and monitoring of latanoprost (LP).

Optical and surface morphological analyses revealed that the as-prepared isomeric GQDs, passivated GQDs, and CS drug hybrid was well characterized. Furthermore, the UV-visible spectroscopy findings, XPS binding energy levels, particulate growth, and zeta potential parameters showed the effective alteration of the nanocomposite.

Future Perspective

Constant improvements will be necessary in the future to perform the durable distribution of LP for prolonged-release dynamics.

The quantity of the dissolved drug of interest may be modified based on lysozyme production in the optical area. However, the existing combination of the CS and GQDs can still be employed as flexible material for an excellent ocular solution, eye drop, and soft lens manufacturing.

The current study is expected to offer up new paths for further research into CS-GQDs incorporated nanocomposites for enzyme-driven medicinal administration, monitoring, non-invasive treatments, and customized contact lenses.


Kumara, B., Shambhu, R., Prabhu, A. and Prasad, K., (2022) Novel chitosan - graphene quantum dots composite for therapeutic delivery and tracking through enzymatic stimuli response. Carbohydrate Polymers, p.119426.

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Hussain Ahmed

Written by

Hussain Ahmed

Hussain graduated from Institute of Space Technology, Islamabad with Bachelors in Aerospace Engineering. During his studies, he worked on several research projects related to Aerospace Materials & Structures, Computational Fluid Dynamics, Nano-technology & Robotics. After graduating, he has been working as a freelance Aerospace Engineering consultant. He developed an interest in technical writing during sophomore year of his B.S degree and has wrote several research articles in different publications. During his free time, he enjoys writing poetry, watching movies and playing Football.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Ahmed, Hussain. (2022, April 06). New Antiglaucoma Nano-Based Drug Carrier Proposed. AZoNano. Retrieved on March 02, 2024 from

  • MLA

    Ahmed, Hussain. "New Antiglaucoma Nano-Based Drug Carrier Proposed". AZoNano. 02 March 2024. <>.

  • Chicago

    Ahmed, Hussain. "New Antiglaucoma Nano-Based Drug Carrier Proposed". AZoNano. (accessed March 02, 2024).

  • Harvard

    Ahmed, Hussain. 2022. New Antiglaucoma Nano-Based Drug Carrier Proposed. AZoNano, viewed 02 March 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Azthena logo powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.